Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chunxia Su

Showing results (171-180 of 223) with videos related to

Pageof 23
Sort By:
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|January 23, 2018
Uncommon <i>EGFR</i> mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinum-based chemotherapyJinpeng Shi, Hui Yang, Tao Jiang, et al.
Cancer Cell International|June 10, 2026
A cilia-associated signature predicts resistance to anti-PD-1 immune checkpoint blockade therapy in lung adenocarcinomaFei Zhou, Gaohua Feng, Xiaoshen Zhang, et al.
Lung Cancer (Amsterdam, Netherlands)|June 19, 2022
Predicting checkpoint inhibitors pneumonitis in non-small cell lung cancer using a dynamic online hypertension nomogramXiaohui Jia, Xiangling Chu, Lili Jiang, et al.
Lung Cancer (Amsterdam, Netherlands)|July 2, 2022
Erratum to "Predicting checkpoint inhibitors pneumonitis in non-small cell lung cancer using a dynamic online hypertension nomogram" [Lung Cancer 170 (2022) 74-84]Xiaohui Jia, Xiangling Chu, Lili Jiang, et al.
Lung Cancer (Amsterdam, Netherlands)|January 16, 2019
Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790MSha Zhao, Xuefei Li, Chao Zhao, et al.
Cancer|May 10, 2012
Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinomaShengxiang Ren, Xiaoxia Chen, Peng Kuang, et al.
Thoracic Cancer|February 23, 2019
Larger tumors are associated with inferior progression-free survival of first-line EGFR-tyrosine kinase inhibitors and a lower abundance of EGFR mutation in patients with advanced non-small cell lung cancerYingying Pan, Guanghui Gao, Xiaoxia Chen, et al.
Lung Cancer (Amsterdam, Netherlands)|April 5, 2022
Characteristics of Notch signaling pathway and its correlation with immune microenvironment in SCLCWei Li, Lingyun Ye, Yan Huang, et al.
Translational Lung Cancer Research|December 3, 2021
The safety and efficacy of immunotherapy with anti-programmed cell death 1 monoclonal antibody for lung cancer complicated with <i>Mycobacterium tuberculosis</i> infectionJinpeng Shi, Jiayu Li, Qi Wang, et al.
Lung Cancer (Amsterdam, Netherlands)|February 5, 2022
Real-world clinical outcomes of neoadjuvant immunotherapy combined with chemotherapy in resectable non-small cell lung cancerJunqi Wu, Likun Hou, Haoran E, et al.
Pageof 23

Showing results (171-180 of 223) with videos related to

Sort By:
Pageof 23
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|January 23, 2018
Uncommon <i>EGFR</i> mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinum-based chemotherapyJinpeng Shi, Hui Yang, Tao Jiang, et al.
Cancer Cell International|June 10, 2026
A cilia-associated signature predicts resistance to anti-PD-1 immune checkpoint blockade therapy in lung adenocarcinomaFei Zhou, Gaohua Feng, Xiaoshen Zhang, et al.
Lung Cancer (Amsterdam, Netherlands)|June 19, 2022
Predicting checkpoint inhibitors pneumonitis in non-small cell lung cancer using a dynamic online hypertension nomogramXiaohui Jia, Xiangling Chu, Lili Jiang, et al.
Lung Cancer (Amsterdam, Netherlands)|July 2, 2022
Erratum to "Predicting checkpoint inhibitors pneumonitis in non-small cell lung cancer using a dynamic online hypertension nomogram" [Lung Cancer 170 (2022) 74-84]Xiaohui Jia, Xiangling Chu, Lili Jiang, et al.
Lung Cancer (Amsterdam, Netherlands)|January 16, 2019
Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790MSha Zhao, Xuefei Li, Chao Zhao, et al.
Cancer|May 10, 2012
Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinomaShengxiang Ren, Xiaoxia Chen, Peng Kuang, et al.
Thoracic Cancer|February 23, 2019
Larger tumors are associated with inferior progression-free survival of first-line EGFR-tyrosine kinase inhibitors and a lower abundance of EGFR mutation in patients with advanced non-small cell lung cancerYingying Pan, Guanghui Gao, Xiaoxia Chen, et al.
Lung Cancer (Amsterdam, Netherlands)|April 5, 2022
Characteristics of Notch signaling pathway and its correlation with immune microenvironment in SCLCWei Li, Lingyun Ye, Yan Huang, et al.
Translational Lung Cancer Research|December 3, 2021
The safety and efficacy of immunotherapy with anti-programmed cell death 1 monoclonal antibody for lung cancer complicated with <i>Mycobacterium tuberculosis</i> infectionJinpeng Shi, Jiayu Li, Qi Wang, et al.
Lung Cancer (Amsterdam, Netherlands)|February 5, 2022
Real-world clinical outcomes of neoadjuvant immunotherapy combined with chemotherapy in resectable non-small cell lung cancerJunqi Wu, Likun Hou, Haoran E, et al.
Pageof 23